Carey Kimmelstiel, MD
Cardiovascular Disease · Boston, MANPI 1043326713
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $335,138 of the $484,280 with a category attached, or 69.2%. 34 manufacturers reported payments, led by Edwards Lifesciences at 29.8% of the total. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 934 payments — averaging $518.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$144K
- Boston Scientific$98K
- Johnson & Johnson$81K
- GE HealthCare$51K
- Shockwave Medical, Inc$30K
- Chiesi USA, Inc.$27K
- plus $53K from 28 others
Across 74 payments — averaging $3057.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GE HealthCare$88K
- Abbott$66K
- Boston Scientific$55K
- Shockwave Medical, Inc$18K
- Abiomed$272
What the payments were for
- Consulting fees$335,13869%
- Speaking & faculty fees$115,07324%
- Travel & lodging$22,1385%
- Food & beverage$11,9322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 476 | $144,475 |
| Boston Scientific | 170 | $98,094 |
| Johnson & Johnson | 76 | $81,158 |
| GE HealthCare | 20 | $50,628 |
| Shockwave Medical, Inc | 5 | $30,267 |
| Chiesi USA, Inc. | 25 | $26,915 |
| Abbott | 58 | $26,182 |
| Procyrion, Inc. | 4 | $18,638 |
| Medtronic(2 entities) | 33 | $3,858 |
| Abiomed | 11 | $2,139 |
| Boehringer Ingelheim | 8 | $226 |
| Novartis | 8 | $188 |
| Pfizer | 6 | $176 |
| Acist Medical Systems, Inc. | 1 | $147 |
| Teleflex LLC | 2 | $136 |
| Cordis US CORP. | 1 | $123 |
| B. Braun Interventional Systems Inc. | 1 | $122 |
| Amgen | 5 | $117 |
| W. L. Gore & Associates, Inc. | 1 | $115 |
| Angiodynamics, Inc. | 2 | $114 |
| Biotronik Inc. | 1 | $81 |
| AstraZeneca | 4 | $75 |
| Acacia Pharma Inc | 2 | $42 |
| Vifor Pharma, Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Cardiva Medical, Inc. | 2 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Merck | 1 | $25 |
| Novo Nordisk | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Bayer | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Heartflow, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$79,594
- CLINICAL TRIAL PRODUCT$55,351
- KENGREAL$26,816
- AORTIX SYSTEM$18,638
- AMPLATZER$14,711
- GENERAL - STRUCTURAL HEART$11,410
- GENERAL VASCULAR ACCESS$6,114
- MitraClip System$4,976
- GENERAL - STENTS$3,940
- AMPLATZER Occluders$3,160
- AMPLATZER TALISMAN$1,966
- Impella$1,760
- ALLIA$690
- CROSSBOSS$500
- CoreValve Evolut$450
- RESOLUTE ONYX$445
- EVOQUE$314
- GENERAL - THERAPIES$262
- SYMPLICITY G3$175
- CVI SYSTEMS$147
How this compares
$484,280 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 12 | $6,532 |
| Atorvastatin Calcium | 11 | $164 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.